Source: International Congress 2015 – IPF: from bench to bedside
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Paola Faverio (Limbiate, Italy), Paola Faverio, Roberto Ruggiero, Valentina Paolini, Luca Novelli, Federica De Giacomi, Alice Biffi, Elisa Oggionni, Luca Bilucaglia, Alberto Pesci. Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2015; 46: Suppl. 59, 3045

Member's Comments

No comment yet.

Related content which might interest you: High-dose acetylcysteine in idiopathic pulmonary fibrosis Source: ISSN=ISSN 1810-6838, ISBN=, page=358 Year: 2006 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses Source: Eur Respir J 2011; 38: 1487-1489 Year: 2011 Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia Source: Eur Respir J 2005; 25: 528-533 Year: 2005 Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids Source: Breathe, 16 (3) 200086; 10.1183/20734735.0086-2020 Year: 2020 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pulse therapy of corticosteroids in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Acute exacerbation of idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 792 Year: 2004 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Prognostic factors analysis of patients with acute exacerbation of idiopathic interstitial pneumonias treated by polymyxin B hemoperfusion Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 A proof of concept study by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Idiopathic pulmonary haemosiderosis revisited Source: Eur Respir J 2004; 24: 162-169 Year: 2004